PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

Intelligent OMICS partners with Janssen on AI-driven research

The AI platform and expertise will be combined to discover novel targets for haematological cancers.

Intelligent OMICS, a biotechnology company that applies artificial intelligence (AI) to accelerate drug discovery, has announced a target discovery collaboration with Janssen Research & Development, one of the Janssen Pharmaceutical Companies of Johnson & Johnson.

The partnership will combine Intelligent OMICS’ proprietary AI platform, which integrates multi-omics data and deep learning algorithms to uncover novel disease mechanisms and therapeutic opportunities for treatment, with Janssen’s expertise in data science, oncology research and development.

Under the terms of the agreement, Intelligent OMICS will receive an upfront payment and research support from Janssen, as well as potential milestone payments based on the successful development of products resulting from the collaboration.

The collaboration is expected to generate new insights into the molecular biology of haematological cancers and identify potential new targets for treatment. This could lead to the development of new and more effective therapies for these diseases.

Dr Robert Grundy, chief executive officer of Intelligent OMICS, concluded: “We are thrilled to be working with Janssen and their oncology discovery and data science experts to apply our AI platform to haematological cancers, which are among the most challenging and complex diseases to treat.”

He added: “We believe that our AI platform can generate novel insights into the molecular drivers of these cancers and identify new ways to intervene therapeutically.”

The link-up demonstrates the potential of AI to accelerate drug discovery and the commitment of both companies to establish new treatments for cancer.

The collaboration is expected to last for three years.

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026